LNC
VRTX icon

Lincoln National Corp’s Vertex Pharmaceuticals VRTX Stock Holding History

Lincoln National Corp’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,608
Closed -$1.09M – 1103
2024
Q1 		$1.09M Buy
2,608
+548
+27% +$232K 0.02% 492
2023
Q4 		$838K Buy
2,060
+714
+53% +$264K 0.01% 507
2023
Q3 		$468K Buy
1,346
+154
+13% +$53.9K 0.01% 626
2023
Q2 		$419K Sell
1,192
-1,172
-50% -$395K 0.01% 666
2023
Q1 		$745K Buy
2,364
+34
+1% +$10.2K 0.02% 463
2022
Q4 		$673K Buy
2,330
+874
+60% +$266K 0.02% 456
2022
Q3 		$422K Buy
1,456
+101
+7% +$29.1K 0.01% 542
2022
Q2 		$382K Buy
1,355
+17
+1% +$4.55K 0.01% 560
2022
Q1 		$349K Buy
1,338
+68
+5% +$16.1K 0.01% 668
2021
Q4 		$278K Sell
1,270
-1
-0.1% -$194 0.01% 737
2021
Q3 		$231K Buy
1,271
+246
+24% +$48K 0.01% 782
2021
Q2 		$206K Buy
+1,025
New +$214K ﹤0.01% 803

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Lincoln National Corp's VRTX Position: Q2 2024 in Review

Lincoln National Corp sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 2,608 shares — an estimated $1.09M sold.

Lincoln National Corp first reported a position in VRTX in Q2 2021 and held it in 12 quarters. The position peaked at $1.09M in Q1 2024. 1,550 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

  • Lincoln National Corp reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Lincoln National Corp sold 2,608 Vertex Pharmaceuticals shares in Q2 2024, an estimated $1.09M.
  • Lincoln National Corp first reported a position in Vertex Pharmaceuticals in Q2 2021 and held it in 12 quarters.
  • Lincoln National Corp's Vertex Pharmaceuticals position peaked at $1.09M in Q1 2024.
  • 1,550 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on Lincoln National Corp's 13F filing for Q2 2024, filed 25 Jul 2024.